REGENXBIO, Inc. (RGNX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about REGENXBIO, Inc. (RGNX)
Company Performance

Current Price

as of Oct 16, 2024

$10.75

P/E Ratio

N/A

Market Cap

$531.3M

Description

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Metrics

Overview

  • HQRockville, MD
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerRGNX
  • Price$10.75+4.37%

Trading Information

  • Market Cap$531.30M
  • Float90.05%
  • Average Daily Volume (1m)585,487
  • Average Daily Volume (3m)497,832
  • EPS-$5.27

Company

  • Revenue$89.04M
  • Rev Growth (1yr)11.60%
  • Net Income-$52.99M
  • Gross Margin34.38%
  • EBITDA Margin-233.17%
  • EBITDA-$51.99M
  • EV$460.39M
  • EV/Revenue5.17
  • P/EN/A
  • P/S6.11
  • P/B1.52
Documents
SEC Filings
8-K (2024-09-17)
8-K (2024-08-06)
8-K (2024-08-01)
8-K (2024-06-13)
8-K (2024-06-03)
8-K (2024-05-08)
8-K (2024-03-11)
8-K (2024-02-27)
8-K (2023-11-08)
8-K (2023-09-01)
8-K (2023-08-02)
8-K (2023-06-05)
8-K (2023-05-03)
8-K (2023-02-28)
8-K (2023-01-10)
10-Q (2024-08-01)
10-Q (2024-05-08)
10-Q (2023-11-08)
10-Q (2023-08-02)
10-Q (2023-05-03)
10-K (2024-02-27)
10-K (2023-02-28)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-08)
Earnings Report (2023-08-02)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: REGENXBIO Q3 ($16.41, 0.00) (2023-11-09T00:21:51Z)
REGENXBIO presents interim clinical data from Phase I/II AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy ($16.52, 0.00) (2023-10-03T20:08:16Z)
REGENXBIO presents additional data from Phase II ALTITUDE trial of ABBV-RGX-314; conference call 6-Nov ($15.33, 0.00) (2023-11-03T23:09:27Z)
REGENXBIO Announces pipeline prioritization and corporate restructuring ($16.41, 0.00) (2023-11-08T21:09:27Z)
REGENXBIO announces dose escalation in AFFINITY DUCHENNE trial ($19.22, 0.00) (2023-11-29T12:06:40Z)
Follow-up: REGENXBIO reports Q3 EPS ($1.41) vs FactSet ($1.46) [10 est, ($1.74)-(0.91)] ($16.41, 0.00) (2023-11-08T21:11:02Z)